TABLE 6.
In vivo efficacy of NPs and free drugs against B. melitensis in the chronic phase.
| Treatment | Chronic stage | |||
|---|---|---|---|---|
| CFUs (Log10) in spleen | Log CFUs reduction | CFUs (Log10) in liver | Log CFUs reduction | |
| Untreated (control) | 3.2 ± 0.03 | 0.0 | 2.8 ± 0.04 | 0.0 |
| DOX-SLN | 2.3 ± 0.04 | 0.9 | 1.9 ± 0.03 | 0.9 |
| HCQ-SLN | 3.02 ± 0.03 | 0.18 | 2.7 ± 0.02 | 0.1 |
| DOX-HCQ-SLN | 1.6 ± 0.01 | 1.6 | 1.3 ± 0.04 | 1.5 |
| Free doxycycline | 2.8 ± 0.05 | 0.4 | 2.4 ± 0.07 | 0.4 |
| Free hydroxychloroquine | 3.0 ± 0.08 | 0.2 | 2.7 ± 0.06 | 0.1 |
| Free DOX-HCQ (Mix) | 2.5 ± 0.04 | 0.7 | 2.0 ± 0.05 | 0.8 |
| Free SLN | 3.05 ± 0.07 | 0.15 | 2.9 ± 0.04 | 0.1 |